A VISION TO CURE CANCER THROUGH NEXT GENERATION CANCER VACCINES.

Genocea harnesses the power of T cells to discover life-changing vaccines and immunotherapies. While traditional discovery methods have largely used in silico methods to propose T cell targets, or antigens, we use ATLASTM, our proprietary technology platform, to identify clinically relevant T cell antigens based on patients’ own T cell immune responses to their cancers. We are using ATLAS’s superiority in antigen identification to develop neoantigen cancer vaccines with our lead candidate, GEN-009, expected to enter clinical development in early 2018.

#TARGETSMATTER

Choosing the right vaccine antigens is the decisive Genocea difference

Neoantigen Cancer Vaccine Pipeline

 Genocea understands that cancer is personal. We are leveraging our ATLAS platform to identify new targets that are specific to each individual. Our expertise in vaccinology enables us to turn those targets into personalized cancer vaccines.